Leading Industry Analyst Evaluates Dendrite's Cost-Effective Sales Force Effectiveness Solutions

Gartner, Inc., recently evaluated the cost-effective Sales Force Effectiveness (SFE) solutions offered by Dendrite International, Inc., (NASDAQ: DRTE), a global leader in providing solutions to the life sciences industry. The Gartner report, "Dendrite Asserts Leadership in Cost-Effective Biopharma SFA Solutions,” analyzes the company’s new SFE solutions in comparison to its traditional SFE approaches. Dendrite’s cost-effective SFE solutions are highlighted by its launch of Dendrite MICRO™, a smartphone-based SFE solution built specifically for small- and mid-sized pharmaceutical companies. Last year, Dendrite also introduced j-force WIRELESS™, which is a SFE solution using mobile phones for the Asian market. "We design our products and services to meet the unique needs of our life science clients,” said Subhash Vaid, Dendrite’s vice president of Product Management. "We offer a comprehensive SFE suite that’s easy to use, easy to deploy, and easily configured to meet the unique needs of life science companies of all sizes.” Dendrite’s flagship SFE solution, Mobile Intelligence™, is specially configured for mid- to large-size life science companies and was engineered to mirror a sales representative’s work flow to maximize efficiency. The company also markets SFE solutions that use web interfaces. An electronic version of the Gartner report is available at www.dendrite.com/gartner. About Dendrite Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, marketing, clinical and compliance solutions for the global, pharmaceutical industry. The Company's clients are located in more than 50 countries and include the world's top 20 pharmaceutical companies. For more information, please visit www.dendrite.com. Note: Dendrite is a registered trademark of Dendrite International, Inc. This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.